Article

Bausch & Lomb lens wins 2008 medical design excellence awards competition

Bausch & Lomb announced that its micro-incision IOL (Akreos AO MI60) has received the 2008 Medical Design Excellence Award.

Bausch & Lomb announced that its micro-incision IOL (Akreos AO MI60) has received the 2008Medical Design Excellence Award.

In keeping with company's drive for smaller cataract incisions and better patient outcomes, theIOL was designed for implantation through a 1.8-mm incision, the company said. The lens can beinserted through a micro-incision due to its strong yet flexible acrylic base material,according to the company.

"With [this lens] and the vision enhancement system [Stellaris], accommodating both 1.8-mmcoaxial and biaxial techniques, Bausch & Lomb is the only company . . . that can offer such acomplete solution for micro-incision cataract surgery," Dr. Joel Pynson, MD, director, designengineering who led the IOL project team.

"As part of our innovative, industry-leading lens portfolio the [lens] provides surgeons withoptions that deliver the outcomes their patients demand," said Alan Farnsworth, corporate vicepresident and president, Europe, Middle East and Africa region.

The IOL is available in Europe and Asia. It is not yet approved for use in the UnitedStates.

For more information, visit Bausch & Lomb at booth 828.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.